Dietary Vitamin D₃ Restriction Influences Tumor Growth, but not the Ability to Generate an Antigen-Specific Immune Response in OTII Transgenic Mice

REFERENCES

• Adorini L., Penna G., Giarratana N., Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune disease. J. Cell. Biochem. 2003; 88: 227–233
   PubMed Web of Science ®Google Scholar
• Aslakson C. J., Miller F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992; 52: 1399–1405
   PubMed Web of Science ®Google Scholar
• Barnden M. J., Allison J., Heath W. R., Carbone F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 1998; 76: 34–40
   PubMed Web of Science ®Google Scholar
• DeLuca H. F. Overview of general physiological features and functions of vitamin D. Am. J. Clin. Nutr. 2004; 80: 1689S–1696S
   PubMed Web of Science ®Google Scholar
• Grant W. B. An ecological study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002; 94: 272–281
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir H., Wells A. D., Turka L. A. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J. Immunol. 1999; 162: 5212–5223
   PubMed Web of Science ®Google Scholar
• Harris D. M., Go V. L. W. Vitamin D and colon carcinogenesis. J. Nutr. 2004; 134: 3463S–3471S
   PubMed Web of Science ®Google Scholar
• Hewison M. Vitamin D and innate immunity. Curr. Opin. Investig. Drugs 2008; 9: 485–490
   PubMed Web of Science ®Google Scholar
• Hogquist K. A., Jameson S. C., Heath W. R., Howard J. L., Bevan M. J., Carbone F. R. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17–27
   PubMed Web of Science ®Google Scholar
• Imazeki I., Matsuzaki J., Tsuji K., Nishimura T. Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed. Res. 2006; 27: 1–9
   PubMed Web of Science ®Google Scholar
• James S. Y., Mackay A. G., Colston K. W. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Ster. Biochem. Mol. Biol. 1996; 58: 395–401
   PubMed Web of Science ®Google Scholar
• Janowsky E. C., Lester G. E., Weinberg C. R., Millikan R. C., Schildkraut J. M., Garrett P. A., Hulka B. S. Association between low levels of 1,25-dihydroxyvitamin D3 and breast cancer risk. Publ. Health Nutr. 1999; 2: 283–291
   PubMed Web of Science ®Google Scholar
• Jensen S., Madsen M. W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1,25-dihyroxyvitamin D3 on the G1-S phase controlling machinery. Mol. Endocrinol. 2001; 15: 1370–1380
   PubMed Web of Science ®Google Scholar
• Jirapongsananuruk O., Melamed I., Leung D. Y. M. Additive immunosuppressive effects of 1,25-dihydroxyvitamin D3 and corticosteroids on Th1, but not Th2, responses. J. Allergy Clin. Immmunol. 2000; 106: 981–985
   PubMed Web of Science ®Google Scholar
• John E. M., Schwartz G. G., Dreon D. M., Koo J. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow up study, 1971–1975 to 1992. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 399–406
   PubMed Web of Science ®Google Scholar
• Jones G., Strugnell S. A., DeLuca H. F. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 1998; 78: 1193–1231
   PubMed Web of Science ®Google Scholar
• Lappe J. M., Travers-Gustafson D., Davies K. M., Recker R. R., Heaney R. P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007; 85: 1586–1591
   PubMed Web of Science ®Google Scholar
• Majewski S., Kutner A., Jablonska S. Vitamin D analogs in cutaneous malignancies. Curr. Pharm. Des. 2000; 6: 829–838
   Google Scholar
• Matheu V., Back O., Mondoc E., Issazadeh-Navikas S. Dual effects of vitamin D-induced alterations of Th1/Th2 cytokine expression: enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J. Allergy Clin. Immunol. 2003; 112: 585–592
   PubMed Web of Science ®Google Scholar
• Matsuzaki J., Tsuji T., Zhang Y., Waiko D., Imazeki I., Sakai T., Ikeda H., Nishimura T. 1α, 25-dihydroxyvitamin D3 downmodulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lymphocyte generation. Cancer Sci. 2006; 97: 139–147
   PubMed Web of Science ®Google Scholar
• Miller F. R., Heppner G. H. Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J. Natl. Cancer Inst. 1979; 63: 1457–1463
   PubMedGoogle Scholar
• Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. 1α,25-Dihydroxyvitamin D3 is a preventative factor in metastasis of lung cancer. Carcinogenesis 2005; 26: 429–440
   PubMed Web of Science ®Google Scholar
• Nurnberg B., Schadendorf S., Gartner B., Pfohler C., Herrmann W., Tilgen W., Reicrath J. Progression of malignant melanoma is associated with reduced 25-hydroxyvitamin D serum levels. Exp. Dermatol. 2008; 17: 627
   Google Scholar
• Penna G., Amuchastegui S., Giarratana N., Daniel K. C., Vulcano M., Sozzani S., Adorini L. 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 2007; 178: 145–153
   PubMed Web of Science ®Google Scholar
• Pichler J., Gerstmayr M., Szepfalusi Z., Urbanek R., Peterlik M., Willheim M. 1α25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Ped. Res. 2002; 52: 12–18
   PubMed Web of Science ®Google Scholar
• Rockwell S. C., Kallman R. F., Fajardo L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 1972; 49: 735–749
   PubMedGoogle Scholar
• Schwartz G. G. Vitamin D and the epidemiology of prostate cancer. Semin. Dial. 2005; 18: 276–289
   PubMed Web of Science ®Google Scholar
• Skinner H. G., Michaud D. S., Giovannucci E., Willett W. C., Colditz G. A., Fuchs C. S. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1688–1695
   PubMed Web of Science ®Google Scholar
• Staeva-Vieira T. P., Freedman L. P. 1,25-Dihydroxyvitamin D3 inhibits IFN-γ and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J. Immunol. 2002; 168: 1181–1189
   PubMed Web of Science ®Google Scholar
• Suda T., Ueno Y., Fujii K., Shinki T. Vitamin D and bone. J. Cell Biochem. 2002; 88: 259–266
   Google Scholar
• Tokar E. J., Webber M. M. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin. Exp. Metastasis 2005; 22: 275–284
   PubMed Web of Science ®Google Scholar
• Wietrzyk J., Nevozhay D., Filip B., Milczarek M., Kutner A. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 2007; 27: 3387–3398
   PubMed Web of Science ®Google Scholar